Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of PD-1 signaling in health and immune-related diseases
Ruyue Chen, Yun Zhu, Yunyan Shen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Regulation of Treg cells by cytokine signaling and co-stimulatory molecules
Yuan Zong, Kaihang Deng, Wai Po Chong
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 24
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Tianye Li, Mengke Niu, Jianwei Zhou, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Miguel Á. Ortega, Diego Liviu Boaru, Diego De León-Oliva, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 8, pp. 987-1000
Closed Access | Times Cited: 11
Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach
Tian Bu, Wenlong Yang, Jian Zhao, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 379-379
Open Access | Times Cited: 1
Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy
Qiaohong Geng, Peifu Jiao
Molecules (2024) Vol. 29, Iss. 2, pp. 454-454
Open Access | Times Cited: 7
Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1
Ana Dillen, Indy Bui, Megan Jung, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1237-1237
Open Access | Times Cited: 6
Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis
Xin Shen, Jun Yang, Geng Qian, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials
Francisco Cézar Aquino de Moraes, Artur de Oliveira Macena Lôbo, Vitor Kendi Tsuchiya Sano, et al.
Clinical Oncology (2024) Vol. 36, Iss. 10, pp. e408-e419
Closed Access | Times Cited: 5
Systematic Review on the Effectiveness and Outcomes of Nivolumab Treatment Schemes in Advanced and Metastatic Cervical Cancer
Ion Petre, Corina Vernic, Izabella Petre, et al.
Diseases (2024) Vol. 12, Iss. 4, pp. 77-77
Open Access | Times Cited: 4
Reduced expression of programmed cell death protein 1 on peripheral regulatory B cells in pre-eclampsia–signs of impaired immune suppression
Sophie Brondt Salby, Gry Persson, N Pedersen, et al.
Journal of Reproductive Immunology (2025) Vol. 168, pp. 104426-104426
Open Access
Genetic variants in PD-1 and its ligands, gene–gene and gene–environment interactions in allergic rhinitis
Ruoxi Chen, Zhihui Luan, Chong Shen, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113912-113912
Closed Access
A combination treatment with a water extract from Euglena gracilis and anti-PD-1 antibody strongly inhibits growth of lung cancer in mice through stimulating tumor-infiltrating lymphocytes
Susumu Ishiguro, Sarah DeVader, C. C. F. Blake, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113953-113953
Closed Access
Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease
Katarzyna Cieplińska, Emilia Niedziela, Agata Kopacz Rdzanek, et al.
Cytokine (2025) Vol. 187, pp. 156862-156862
Closed Access
Cellular and immune landscape of chronic liver diseases: insights from immunophenotyping
Sina Soleimani, Özgür Albayrak, Kayra Somay, et al.
Frontiers in Molecular Biosciences (2025) Vol. 11
Open Access
Molecular Mechanisms of Immune Regulation: A Review
Borros Arneth
Cells (2025) Vol. 14, Iss. 4, pp. 283-283
Open Access
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells
Tânia Moura, Paula Laranjeira, Olga Caramelo, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 143-143
Open Access
Identification of inflammatory protein biomarkers for predicting the different subtype of adult with tuberculosis: an Olink proteomic study
Yunlin Song, Buzukela Abuduaini, Xinting Yang, et al.
Inflammation Research (2025) Vol. 74, Iss. 1
Open Access
PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities
Mojdeh Soltani, Mohammad Abbaszadeh, Hamed Fouladseresht, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15233-15233
Open Access | Times Cited: 12
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
Filomena Marino Carvalho
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
The Dual Role of Chaperone-mediated Autophagy in the Response and Resistance to Cancer Immunotherapy
Mohammadreza Saberiyan, Sarah Gholami, Mahsa Ejlalidiz, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 210, pp. 104700-104700
Open Access
Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Nicia I. Profili, Roberto Castelli, Antonio Gidaro, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 5161-5161
Open Access | Times Cited: 9
Sintilimab treatment for chronic active Epstein–Barr virus infection and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children
Ruyue Chen, Qiang Lin, Yun Zhu, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 9
Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibition for Malignancies
Shlomit Shalitin
Hormone Research in Paediatrics (2024), pp. 1-12
Closed Access | Times Cited: 3
Immune checkpoint molecules in solid organ transplantation: A promising way to prevent rejection
I. Righi, Daria Trabattoni, Lorenzo Rosso, et al.
Immunology Letters (2024) Vol. 267, pp. 106860-106860
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top